Perifosine in Treating Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer

Completed · Phase 2

Conditions studied: Pancreatic Cancer

In brief

RATIONALE: Perifosine may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of perifosine in treating patients who have locally advanced, unresectable, or metastatic pancreatic cancer.

Key facts

Study ID

NCT00059982

Run by

Eastern Cooperative Oncology Group

Starts

2003-07-01

Expected to finish

2005-08-01

Last updated by the study team

2013-06-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• CCOP - Carle Cancer Center — Urbana, Illinois, United States
• CCOP - Northern Indiana CR Consortium — South Bend, Indiana, United States
• CCOP - Iowa Oncology Research Association — Des Moines, Iowa, United States
• Tufts - New England Medical Center — Boston, Massachusetts, United States
• CCOP - Duluth — Duluth, Minnesota, United States
• Mayo Clinic Cancer Center — Rochester, Minnesota, United States
• CCOP - Metro-Minnesota — Saint Louis Park, Minnesota, United States
• MBCCOP-Our Lady of Mercy Cancer Center — The Bronx, New York, United States
• CCOP - Merit Care Hospital — Fargo, North Dakota, United States
• CCOP - Scott and White Hospital — Temple, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.